PE44997A1 - Formulacion oral de 2-metil-tieno-benzodiacepina (olanzapina) y procedimiento de preparacion - Google Patents
Formulacion oral de 2-metil-tieno-benzodiacepina (olanzapina) y procedimiento de preparacionInfo
- Publication number
- PE44997A1 PE44997A1 PE1996000204A PE00020496A PE44997A1 PE 44997 A1 PE44997 A1 PE 44997A1 PE 1996000204 A PE1996000204 A PE 1996000204A PE 00020496 A PE00020496 A PE 00020496A PE 44997 A1 PE44997 A1 PE 44997A1
- Authority
- PE
- Peru
- Prior art keywords
- olanzapine
- oral formulation
- hydroxypropilcellulose
- refers
- benzodiacepine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
SE REFIERE A UNA COMPOSICION ANTIPSICOTICA, DONDE: EL PRINCIPIO ACTIVO ES LA FORMA POLIMORFICA ALTAMENTE PURA DE OLANZAPINA DE 1% A 3% P/P, CARACTERIZADO POR VALORES DE ESPACIOS INTERPLANARES DE 10,2689A� A 2,6007A� APROXIMADAMENTE; EL AGENTE DE CARGA ES LACTOSA DE 69,5% A 87,5% P/P, EL AGLUTINANTE ES HIDROXIPROPILCELULOSA DE 3,5 A 4,5% P/P, EL DISGREGANTE ES CROSPOVIDONA DE 4% A 6% P/P, EL AGLUTINANTE SECO ES CELULOSA MICROCRISTALINA DE 9% A 11%; EL LUBRICANTE ES ESTEARATO DE MAGNESIO DE 0,25% A 1%; EN LA RECUBIERTA AL POLIMERO SELECCIONADO ENTRE HIPROMELOSA, HIDROXIPROPILCELULOSA Y ETILCELULOSA, ENTRE OTROS, MAS PREFERIBLEMENTE HIDROXIPROPILHIPROMELOSA; EN EL SOBRECUBRIMIENTO AL HIDROXIPROPILHIPROMELOSA RECUBIERTO ADICIONALMENTE CON UNA PELICULA EN DISPERSION ACUOSA. TAMBIEN SE REFIERE AL PROCEDIMIENTO DE PREPARACION DE UNA FORMULACION ORAL SOLIDA, QUE COMPRENDE LA GRANULACION HUMEDA ACUOSA DE ALTA CIZALLA Y EL SECADO EN LECHO FLUIDO. ESTA FORMULACION NO PERMITE EL CAMBIO DE COLOR FARMACEUTICAMENTE NO ACEPTABLE, BAJO CONDICIONES DE ALMACENAMIENTO
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41046595A | 1995-03-24 | 1995-03-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE44997A1 true PE44997A1 (es) | 1997-10-23 |
Family
ID=23624847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1996000204A PE44997A1 (es) | 1995-03-24 | 1996-03-22 | Formulacion oral de 2-metil-tieno-benzodiacepina (olanzapina) y procedimiento de preparacion |
Country Status (46)
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR5278A (es) * | 1995-03-24 | 1996-07-04 | Lilly Co Eli | Formulacion oral de 2-metil-tieno-benzodiacepina |
| PL332503A1 (en) * | 1996-09-24 | 1999-09-13 | Lilly Co Eli | Coated particles containing preparation |
| US8563522B2 (en) * | 1997-07-08 | 2013-10-22 | The Iams Company | Method of maintaining and/or attenuating a decline in quality of life |
| US20020035071A1 (en) * | 1997-07-08 | 2002-03-21 | Josef Pitha | Mimicking the metabolic effects of caloric restriction by administration of glucose antimetabolites |
| US20060116330A1 (en) * | 1997-07-08 | 2006-06-01 | The Iams Company | Methods of mimicking the metabolic effects of caloric restriction by administration of mannoheptulose |
| US6617321B2 (en) | 1997-09-30 | 2003-09-09 | Eli Lilly And Company | 2-methyl-thieno-benzodiazepine formulation |
| US7022698B2 (en) | 1999-12-28 | 2006-04-04 | U & I Pharmaceuticals, Ltd. | Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof |
| NZ519926A (en) * | 1999-12-28 | 2004-02-27 | Cipla Ltd | New polymorphic forms of olanzapine |
| US6348458B1 (en) | 1999-12-28 | 2002-02-19 | U & I Pharmaceuticals Ltd. | Polymorphic forms of olanzapine |
| US6740753B2 (en) | 2001-01-04 | 2004-05-25 | Geneva Pharmaceuticals, Inc. | Olanzapine crystal modification |
| US20030070584A1 (en) | 2001-05-15 | 2003-04-17 | Cynthia Gulian | Dip coating compositions containing cellulose ethers |
| US20030072731A1 (en) * | 2001-05-15 | 2003-04-17 | Cynthia Gulian | Dip coating compositions containing starch or dextrin |
| US20030072729A1 (en) * | 2001-05-15 | 2003-04-17 | Christopher Szymczak | Simethicone as weight gain enhancer |
| US8309118B2 (en) | 2001-09-28 | 2012-11-13 | Mcneil-Ppc, Inc. | Film forming compositions containing sucralose |
| GB0203061D0 (en) * | 2002-02-08 | 2002-03-27 | Novartis Ag | Organic compounds |
| CA2477088A1 (en) | 2002-02-22 | 2003-10-02 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| WO2003086361A1 (en) * | 2002-04-18 | 2003-10-23 | Dr. Reddy's Laboratories Ltd. | Rapidly dispersing solid oral compositions |
| DE60336226D1 (de) | 2002-05-31 | 2011-04-14 | Sandoz Ag | Verfahren zur herstellung von olanzapin form i |
| SI21270A (sl) * | 2002-07-15 | 2004-02-29 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Kristalne oblike olanzapina in postopki za njihovo pripravo |
| US7429619B2 (en) | 2002-08-02 | 2008-09-30 | Mcneil Consumer Healthcare | Polyacrylic film forming compositions |
| US7029112B2 (en) * | 2002-08-05 | 2006-04-18 | Mars, Incorporated | Ink-jet printing on surface modified edibles and products made |
| US8168170B2 (en) * | 2002-10-03 | 2012-05-01 | The Procter And Gamble Company | Compositions having an inner core and at least three surrounding layers |
| PL202856B1 (pl) * | 2002-12-20 | 2009-07-31 | Adamed Spo & Lstrok Ka Z Ogran | Sposób otrzymywania farmaceutycznie czystej polimorficznej postaci I olanzapiny |
| WO2005009407A2 (en) * | 2003-07-29 | 2005-02-03 | Ranbaxy Laboratories Limited | Oral pharmaceutical formulations of olanzapine |
| US20050112196A1 (en) * | 2003-10-07 | 2005-05-26 | Jianbo Xie | Rapidly disintegrating formulation |
| AU2004291043A1 (en) * | 2003-11-18 | 2005-06-02 | 3M Innovative Properties Company | Olanzapine containing transdermal drug delivery compositions |
| US8877178B2 (en) * | 2003-12-19 | 2014-11-04 | The Iams Company | Methods of use of probiotic bifidobacteria for companion animals |
| US20050152884A1 (en) * | 2003-12-19 | 2005-07-14 | The Procter & Gamble Company | Canine probiotic Bifidobacteria globosum |
| US8894991B2 (en) * | 2003-12-19 | 2014-11-25 | The Iams Company | Canine probiotic Lactobacilli |
| US7785635B1 (en) * | 2003-12-19 | 2010-08-31 | The Procter & Gamble Company | Methods of use of probiotic lactobacilli for companion animals |
| US20050158294A1 (en) * | 2003-12-19 | 2005-07-21 | The Procter & Gamble Company | Canine probiotic Bifidobacteria pseudolongum |
| ES2253091B1 (es) * | 2004-07-27 | 2007-02-01 | Inke, S.A. | Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo. |
| DK1838716T3 (da) | 2005-01-05 | 2011-07-25 | Lilly Co Eli | Olanzapinpamota-dihydrat |
| TWI320783B (en) | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
| PL385455A1 (pl) * | 2005-04-22 | 2008-11-24 | Teva Pharmaceuticals Usa,Inc. | Doustna rozpadająca się farmaceutyczna tabletka preparatów olanzapiny |
| AU2006253007B2 (en) * | 2005-05-31 | 2012-12-20 | Alimentary Health Ltd | Feline probiotic Bifidobacteria |
| CA2609617C (en) * | 2005-05-31 | 2014-07-08 | The Iams Company | Feline probiotic lactobacilli |
| US20070014847A1 (en) * | 2005-07-05 | 2007-01-18 | Ahmed Salah U | Coated capsules and methods of making and using the same |
| NZ564789A (en) * | 2005-07-22 | 2010-07-30 | Myriad Genetics Inc | High drug load formulations and dosage forms |
| WO2007049304A2 (en) * | 2005-10-27 | 2007-05-03 | Jubilant Organosys Limited | Stable coated pharmaceutical formulation of olanzapine and process for preparing the same |
| GB0522474D0 (en) | 2005-11-03 | 2005-12-14 | Actavis Group | A pharmaceutical formulation |
| GB0522473D0 (en) * | 2005-11-03 | 2005-12-14 | Actavis Group | A pharmaceutical formulation |
| ES2279715B1 (es) | 2005-12-26 | 2008-06-01 | Laboratorios Lesvi, S.L. | Formulacion oral de olanzapina. |
| US7834176B2 (en) | 2006-01-26 | 2010-11-16 | Sandoz Ag | Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E |
| US20070293479A1 (en) * | 2006-05-18 | 2007-12-20 | Osinga Niels J | Olanzapine pharmaceutical composition |
| CN101484141A (zh) * | 2006-07-05 | 2009-07-15 | 比利姆制药工业和贸易公司 | 包含抗氧化剂的稳定的奥氮平制剂 |
| AR063043A1 (es) * | 2006-09-29 | 2008-12-23 | Synthon Bv | Composicion farmaceutica de olanzapina |
| RU2436581C2 (ru) | 2007-02-01 | 2011-12-20 | Дзе Иамс Компани | Способ уменьшения воспаления и снижения стресса у млекопитающего |
| EP2246051B1 (en) * | 2008-01-31 | 2013-12-11 | Kyorin Pharmaceutical Co., Ltd. | Method for production of orally rapidly disintegrating tablet comprising imidafenacin as active ingredient |
| US9771199B2 (en) | 2008-07-07 | 2017-09-26 | Mars, Incorporated | Probiotic supplement, process for making, and packaging |
| US20110048048A1 (en) * | 2009-03-25 | 2011-03-03 | Thomas Gielda | Personal Cooling System |
| KR20120093060A (ko) * | 2009-03-25 | 2012-08-22 | 카이틴, 아이엔씨. | 초음파 냉각 시스템 |
| US8505322B2 (en) * | 2009-03-25 | 2013-08-13 | Pax Scientific, Inc. | Battery cooling |
| US20110051549A1 (en) * | 2009-07-25 | 2011-03-03 | Kristian Debus | Nucleation Ring for a Central Insert |
| US10104903B2 (en) | 2009-07-31 | 2018-10-23 | Mars, Incorporated | Animal food and its appearance |
| US8365540B2 (en) * | 2009-09-04 | 2013-02-05 | Pax Scientific, Inc. | System and method for heat transfer |
| WO2012153347A2 (en) | 2011-05-04 | 2012-11-15 | Zentiva K.S. | Oral pharmaceutical composition of olanzapine form 1 |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| US9517212B1 (en) * | 2012-11-15 | 2016-12-13 | Chandra Zaveri | Medicated adhesive pad arrangement |
| CN103919782B (zh) * | 2013-01-15 | 2016-12-28 | 天津药物研究院有限公司 | 一种含有奥氮平的药物组合物及其制备方法 |
| CA2923990A1 (en) * | 2013-09-13 | 2015-03-19 | Bayer Pharma Aktiengesellschaft | Pharmaceutical compositions containing refametinib |
| CN107007559B (zh) * | 2017-04-21 | 2020-05-15 | 浙江京新药业股份有限公司 | 一种稳定的口服药物组合物及其制备方法 |
| EP3630061B1 (en) * | 2017-06-02 | 2024-04-03 | Xeris Pharmaceuticals, Inc. | Precipitation resistant small molecule drug formulations |
| CN113143878A (zh) * | 2021-03-19 | 2021-07-23 | 杭州新诺华医药有限公司 | 奥氮平组合物及其制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4115568A (en) * | 1974-11-26 | 1978-09-19 | Lilly Industries Limited | Thieno[3,2-b]-[1,5]benzodiazepines |
| US4172831A (en) * | 1974-11-26 | 1979-10-30 | Lilly Industries Limited | Thieno-benzodiazepines |
| GB2189698A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
| US4820522A (en) * | 1987-07-27 | 1989-04-11 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
| US5229382A (en) * | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
| GB9009229D0 (en) * | 1990-04-25 | 1990-06-20 | Lilly Industries Ltd | Pharmaceutical compounds |
| ZA922777B (en) * | 1991-04-29 | 1993-10-15 | Lilly Co Eli | Pharmaceutical formulation containing dirithromycin |
| JPH05194225A (ja) * | 1991-11-07 | 1993-08-03 | Yoshitomi Pharmaceut Ind Ltd | 安定化された抗潰瘍剤含有製剤 |
| CA2097016A1 (en) * | 1992-05-29 | 1993-11-30 | John Fairhurst | Pharmaceutical compounds |
| SE9302395D0 (sv) * | 1993-07-09 | 1993-07-09 | Ab Astra | New pharmaceutical formulation |
| US5457101A (en) * | 1994-06-03 | 1995-10-10 | Eli Lilly And Company | Thieno[1,5]benzoidiazepine use |
| CR5278A (es) * | 1995-03-24 | 1996-07-04 | Lilly Co Eli | Formulacion oral de 2-metil-tieno-benzodiacepina |
| US5696115A (en) * | 1995-04-21 | 1997-12-09 | Eli Lilly And Company | Method for treating nicotine withdrawal |
-
1996
- 1996-03-12 CR CR5278A patent/CR5278A/es not_active Application Discontinuation
- 1996-03-21 EG EG25196A patent/EG24077A/xx active
- 1996-03-22 EP EP96301997A patent/EP0733367B1/en not_active Expired - Lifetime
- 1996-03-22 DE DE19681287T patent/DE19681287T1/de not_active Ceased
- 1996-03-22 BR BR9607791A patent/BR9607791A/pt not_active IP Right Cessation
- 1996-03-22 AT AT00204708T patent/ATE284695T1/de active
- 1996-03-22 CA CA002216372A patent/CA2216372C/en not_active Expired - Lifetime
- 1996-03-22 CN CNB96192778XA patent/CN1178662C/zh not_active Expired - Fee Related
- 1996-03-22 JP JP8529533A patent/JPH11502848A/ja active Pending
- 1996-03-22 SI SI9630707T patent/SI1093815T1/xx unknown
- 1996-03-22 ES ES96301997T patent/ES2164837T3/es not_active Expired - Lifetime
- 1996-03-22 EA EA199700260A patent/EA000938B1/ru not_active IP Right Cessation
- 1996-03-22 PL PL96322579A patent/PL188316B1/pl unknown
- 1996-03-22 NZ NZ306111A patent/NZ306111A/xx not_active IP Right Cessation
- 1996-03-22 EP EP00204708A patent/EP1093815B1/en not_active Expired - Lifetime
- 1996-03-22 WO PCT/US1996/003918 patent/WO1996029995A1/en not_active Ceased
- 1996-03-22 AP APAP/P/1997/001064A patent/AP679A/en active
- 1996-03-22 ES ES00204708T patent/ES2232379T3/es not_active Expired - Lifetime
- 1996-03-22 DE DE69634053T patent/DE69634053T2/de not_active Expired - Lifetime
- 1996-03-22 AT AT96301997T patent/ATE206924T1/de active
- 1996-03-22 CO CO96014566A patent/CO4700474A1/es unknown
- 1996-03-22 DK DK00204708T patent/DK1093815T3/da active
- 1996-03-22 RO RO97-01776A patent/RO118370B1/ro unknown
- 1996-03-22 CH CH02246/97A patent/CH691217A5/de not_active IP Right Cessation
- 1996-03-22 HU HU9800410A patent/HU225269B1/hu unknown
- 1996-03-22 GB GB9719817A patent/GB2313783B/en not_active Revoked
- 1996-03-22 KR KR1019970706592A patent/KR100408172B1/ko not_active Expired - Fee Related
- 1996-03-22 TR TR97/01018T patent/TR199701018T1/xx unknown
- 1996-03-22 SK SK1282-97A patent/SK283745B6/sk not_active IP Right Cessation
- 1996-03-22 PT PT96301997T patent/PT733367E/pt unknown
- 1996-03-22 TW TW085103453A patent/TW426526B/zh not_active IP Right Cessation
- 1996-03-22 FI FI973749A patent/FI973749A0/fi unknown
- 1996-03-22 AR ARP960101877A patent/AR002720A1/es not_active Application Discontinuation
- 1996-03-22 PT PT00204708T patent/PT1093815E/pt unknown
- 1996-03-22 UA UA97094738A patent/UA44766C2/uk unknown
- 1996-03-22 SI SI9620041A patent/SI9620041A/sl unknown
- 1996-03-22 CZ CZ19973001A patent/CZ296007B6/cs not_active IP Right Cessation
- 1996-03-22 SI SI9630404T patent/SI0733367T1/xx unknown
- 1996-03-22 EE EE9700328A patent/EE03551B1/xx unknown
- 1996-03-22 DK DK96301997T patent/DK0733367T3/da active
- 1996-03-22 AU AU54280/96A patent/AU696601B2/en not_active Ceased
- 1996-03-22 AR AR33587496A patent/AR001405A1/es not_active Application Discontinuation
- 1996-03-22 MY MYPI96001086A patent/MY113440A/en unknown
- 1996-03-22 PE PE1996000204A patent/PE44997A1/es not_active IP Right Cessation
- 1996-03-22 IL IL11761196A patent/IL117611A/en unknown
- 1996-03-22 ZA ZA9602338A patent/ZA962338B/xx unknown
- 1996-03-22 DE DE69615887T patent/DE69615887T2/de not_active Expired - Lifetime
- 1996-03-22 AT AT0902296A patent/AT405606B/de not_active IP Right Cessation
- 1996-09-20 US US08/716,922 patent/US5919485A/en not_active Expired - Lifetime
-
1997
- 1997-07-30 LU LU90115A patent/LU90115B1/fr active
- 1997-09-05 SE SE9703206A patent/SE9703206L/xx not_active Application Discontinuation
- 1997-09-16 LT LT97-149A patent/LT4350B/lt not_active IP Right Cessation
- 1997-09-22 BG BG101901A patent/BG62594B1/bg unknown
- 1997-09-22 NO NO19974363A patent/NO320388B1/no not_active IP Right Cessation
- 1997-09-22 IS IS4565A patent/IS1903B/is unknown
- 1997-09-23 DK DK199701090A patent/DK173323B1/da not_active IP Right Cessation
- 1997-09-24 OA OA70083A patent/OA10511A/en unknown
- 1997-10-14 LV LVP-97-199A patent/LV11983B/en unknown
-
1998
- 1998-08-31 US US09/144,188 patent/US6190698B1/en not_active Expired - Lifetime
-
2001
- 2001-01-19 US US09/766,218 patent/US6780433B2/en not_active Expired - Fee Related
-
2004
- 2004-07-08 US US10/887,017 patent/US7229643B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE44997A1 (es) | Formulacion oral de 2-metil-tieno-benzodiacepina (olanzapina) y procedimiento de preparacion | |
| GR880100258A (en) | Preparation method of a mould for the retarded liberating of impuprofene | |
| US5601845A (en) | Pharmaceutical spheroid formulation | |
| CA2654493C (en) | Tablet comprising candesartan cilexetil | |
| ES2083074T3 (es) | Dispositivo de liberacion controlada. | |
| IL143900A0 (en) | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations | |
| BR9912300A (pt) | Composição farmacêutica oral de um composto tendo atividade antifúngica e método para a sua preparação | |
| KR20010062478A (ko) | 경구투여후 트리메트아지딘의 지속적 방출을 가능케 하는매트릭스 정제 | |
| KR920019340A (ko) | 최적화된 정제 제제 | |
| PE27899A1 (es) | Formulacion de particulas revestidas | |
| RU2311906C2 (ru) | Композиция препарата замедленного высвобождения для высвобождения ингибитора секреции кислоты в желудке и способ ее получения | |
| ES2317313T3 (es) | Composicion farmaceutica solida que comprende clorhidrato de donepezilo. | |
| PE20000329A1 (es) | Derivados de indol y composiciones farmaceuticas que los contienen | |
| NO178338C (no) | Analogifremgangsmåte for fremstilling av en terapeutisk aktiv benzimidazolforbindelse samt mellomprodukt | |
| ES2090490T3 (es) | Supositorios de liberacion prolongada y un procedimiento para su preparacion. | |
| JP2002518334A5 (es) | ||
| RU2004122479A (ru) | Содержащая свехчистую флудару пероральная композиция с быстрым высвобождением действующего вещества | |
| ATE84711T1 (de) | Trockene orale theophyllinzubereitung mit verzoegerter freisetzung. | |
| WO2005107716A1 (en) | Controlled release paroxetine-containing tablets based on a core and a coating | |
| WAN et al. | Liquid penetration into tablets containing surfactants | |
| CO4970814A1 (es) | Formulaciones de tiagabine de liberacion prolongada con efec tos secundarios reducidos | |
| KR950031064A (ko) | 젬피브로질 함유 약제학적 조성물 | |
| WO1991001714A1 (en) | Ophthalmic composition | |
| CA2191855A1 (en) | Solid pharmaceutical compositions containing (s)-2-(4-isobutylphenyl)propionic acid active ingredient and microcrystalline cellulose and colloidal silica as excipients | |
| JPH0258514U (es) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| MC | Annulment |